The CF community was delivered great news the other week:Â Vertex’s tezacaftor/ivacaftor combination treatment significantly increased…
Reid D'Amico
At the time of writing this column, Reid had started his PhD in biomedical engineering at Vanderbilt University. He uses an engineering approach to research pulmonary hypertension. Reid has CF, and finds much of his drive by experiencing both the research and patient aspects of cystic fibrosis. Reid has also served as a director at the U.S. Adult Cystic Fibrosis Association.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Reid D'Amico
No matter how good I feel, there’s always a sense of anxiety and uncertainty when I walk into a…
Airports can be stressful. With the unpredictable delays, cancellations, and upsets of travel, it’s only natural to take…
For the first time, we see that about 50% of people with cystic fibrosis (CF) are adults. While CF still…
By now, we’ve all heard that steps have been taken toward repealing the Affordable Care Act (ACA). Even within my…
“Brennen Reeves just wanted to be normal. The only problem: the fatal lung disease, cystic fibrosis. The only solution: a double…
My last four articles have highlighted various stem cell types and their potential therapeutic application for those with cystic fibrosis…
My past few articles have touched upon the application of stem cells for the treatment of cystic fibrosis (CF), and…
My last two articles have highlighted how Embryonic Stem Cells (ESCs), Induced Pluripotent Stem Cells (iPSCs), and Gestational…
There are several promising approaches designed to improve the life expectancy and quality of life of those with cystic fibrosis.